Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes


Clinical Trial Description

This study is a randomized, double-blind, placebo-controlled, multiple-doses, parallel-group study to characterize the safety (including the anti-drug antibodies (ADA)), tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TG103 injection. The study will consist of 3 periods: an approximately 4-week screening period, followed by a 12-week treatment period, and a 3-week safety follow-up period. Eligible subjects will be enrolled into three paralleled dose groups (15 mg, 22.5 mg and 30 mg) with 16 subjects in each group. Within each group, subjects will be randomized in a 3:1 ratio to receive TG103 injection or placebo subcutaneously (SC) once a week (QW) over a period of 12 weeks. Each group will be started at a low dose of 7.5 mg and gradually up-titrated at weekly intervals until the target dose. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04855292
Study type Interventional
Source CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Contact Yi Sun
Phone +86 13260872090
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date May 2021
Completion date May 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Active, not recruiting NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Recruiting NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Active, not recruiting NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Recruiting NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Active, not recruiting NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT03362528 - Database and Calibration of a Non-invasive Glucose Monitoring Device N/A
Completed NCT02249871 - Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects Phase 1
Terminated NCT02416193 - Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D) Phase 2
Completed NCT01850615 - Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes Phase 3
Active, not recruiting NCT03936010 - Replication of the CANVAS Diabetes Trial in Healthcare Claims
Active, not recruiting NCT03936049 - Replication of the LEADER Diabetes Trial in Healthcare Claims
Active, not recruiting NCT03936036 - Replication of the CARMELINA Diabetes Trial in Healthcare Claims